Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells |
Qi, Yuan-Ying
(Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University)
Lu, Chao (Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University) Ju, Ying (Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University) Wang, Zi-E (Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University) Li, Yuan-Tang (Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University) Shen, Ya-Juan (Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University) Lu, Zhi-Ming (Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University) |
1 | Aktas E, Kucuksezer UC, Bilgic S, et al (2009). Relationship between CD107a expression and cytotoxic activity. Cell Immunol, 254, 149-54. DOI ScienceOn |
2 | Atzpodien J, Reitz M (2005). Metastatic renal carcinoma longterm survivors treated with s.c. interferon-alpha and s.c. interleukin-2. Cancer Biother Radiopharm, 20, 410-6. DOI ScienceOn |
3 | Chaix J, Tessmer MS, Hoebe K, et al (2008). Cutting edge: priming of NK cells by IL-18. J Immunol, 181, 1627-31. DOI |
4 | Clark JM, Kelley B, Titze J, et al (2013). Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology, 84, 123-6. DOI ScienceOn |
5 | Du G, Ye L, Zhang G, et al (2012). Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-gamma production. J Cancer Res Clin Oncol, 138, 1727-36. DOI ScienceOn |
6 | Gaffen SL, Liu KD (2004). Overview of interleukin-2 function, production and clinical applications. Cytokine, 28, 109-23. DOI ScienceOn |
7 | Kuppala MB, Syed SB, Bandaru S, et al (2012). Immunotherapeutic approach for better management of cancer--role of IL-18. Asian Pac J Cancer Prev, 13, 5353-61. 과학기술학회마을 DOI ScienceOn |
8 | Hu YX, Li M, Jia XH, et al (2013). HPV16 CTL epitope peptideactivated dendritic cell and natural killer co-culture for therapy of cervical cancer in an animal model. Asian Pac J Cancer Prev, 14, 7335-8. DOI ScienceOn |
9 | Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, et al (2014). Molecular bases for the regulation of NKG2D ligands in cancer. Front Immunol, 5, 106. |
10 | Konjevic G, Jurisic V, Jovic V, et al (2012). Investigation of NK cell function and their modulation in different malignancies. Immunol Res, 52, 139-56. DOI ScienceOn |
11 | Marcais A, Viel S, Grau M, et al (2013). Regulation of mouse NK cell development and function by cytokines. Front Immunol, 4, 450. |
12 | Muntasell A, Magri G, Pende D, et al (2010). Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood, 115, 5170-9. DOI ScienceOn |
13 | Ni J, Miller M, Stojanovic A, et al (2012). Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med, 209, 2351-65. DOI |
14 | Robertson MJ, Kirkwood JM, Logan TF, et al (2008). A doseescalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res, 14, 3462-9. DOI ScienceOn |
15 | Son YI, Dallal RM, Lotze MT (2003). Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. J Immunother, 26, 234-40. DOI |
16 | Son YI, Dallal RM, Mailliard RB, et al (2001). Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res, 61, 884-8. |
17 | Segawa S, Goto D, Yoshiga Y, et al (2011). Involvement of NK 1.1-positive gammadeltaT cells in interleukin-18 plus interleukin-2-induced interstitial lung disease. Am J Respir Cell Mol Biol, 45, 659-66. DOI |
18 | Shen Y, Lu C, Tian W, et al (2012). Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol, 40, 1285-90. |
19 | Song H, Hur DY, Kim KE, et al (2006). IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol, 242, 39-45. DOI ScienceOn |
20 | Srivastava S, Pelloso D, Feng H, et al (2013). Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother, 62, 1073-82. DOI ScienceOn |
21 | Tang F, Sally B, Ciszewski C, et al (2013). Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis. PLoS One, 8, e76292. DOI |
22 | Tarhini AA, Millward M, Mainwaring P, et al (2009). A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer, 115, 859-68. DOI ScienceOn |
23 | Wong JL, Berk E, Edwards RP, et al (2013). IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res, 73, 4653-62. DOI ScienceOn |
24 | Tonn T, Schwabe D, Klingemann HG, et al (2013). Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 15, 1563-70. DOI ScienceOn |
25 | Yu DP, Han Y, Zhao QY, et al (2014). CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 2685-8. 과학기술학회마을 DOI ScienceOn |
26 | Vivier E, Tomasello E, Baratin M, et al (2008). Functions of natural killer cells. Nat Immunol, 9, 503-10. DOI ScienceOn |
27 | Yuan CH, Yang XQ, Zhu CL, et al (2014). Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model. Asian Pac J Cancer Prev, 15, 265-71. 과학기술학회마을 DOI ScienceOn |
28 | Zafirova B, Wensveen FM, Gulin M, et al (2011). Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci, 68, 3519-29. DOI |
29 | Zhang C, Zhang J, Niu J, et al (2008). Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol, 69, 490-500. DOI ScienceOn |
30 | Zhao L, Wang WJ, Zhang JN, et al (2014). 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 15, 4039-44. 과학기술학회마을 DOI ScienceOn |
31 | Tse BW, Russell PJ, Lochner M, et al (2011). IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One, 6, e24241. DOI |
32 | Rajbhandary S, Zhao MF, Zhao N, et al (2013). Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways. Asian Pac J Cancer Prev, 14, 5825-31. 과학기술학회마을 DOI ScienceOn |